Medical progress: Renal-cell carcinoma

New England Journal of Medicine

Volumn 335, Issue 12, 1996, Pages 865-875

  Motzer, Robert J ^a,c,d   Bander, Neil H ^b,c   Nanus, David M ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; HEREDITY; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; VON HIPPEL LINDAU DISEASE; GENETICS; KIDNEY TUMOR;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 0030593729     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199609193351207     Document Type: Review

References (150)

1. Kosary CL, McLaughlin JK. Kidney and renal pelvis. In: Miller BA, Ries LAG, Hankey BF, et al., eds. SEER cancer statistics review, 1973-1990. Bethesda, Md.: National Cancer Institute, 1993. (NIH publication no. 93-2789, XI.1-XI.22.)
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
3. Cancer facts & figures - 1996. Atlanta: American Cancer Society, 1996.
4. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
5. McCredie M, Pommer W, McLaughlin JK, et al. International renal-cell cancer study. II. Analgesics. Int J Cancer 1995;60:345-9.
6. Lindblad P, Mellemgaard A, Schlehofer B, et al. International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. Int J Cancer 1995;61:192-8.
7. Mellemgaard A, Lindblad P, Schlehofer B, et al. International renal-cell cancer study. III. Role of weight, height, physical activity and use of amphetamines. Int J Cancer 1995;60:350-4.
8. Mandel JS, McLaughlin JK, Schlehofer B, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995;61:601-5.
9. Wolk A, Gridley G, Niwa S, et al. International renal cell cancer study. VII. Role of diet. Int J Cancer 1996;65:67-73.
10. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF Jr. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst 1984;72:275-84.
11. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986;77:351-6.
12. Wolk A, Lindblad P, Adami H-O. Nutrition and renal cell cancer. Cancer Causes Control 1996;7:5-18.
13. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993;22:135-9.
14. Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. Urology 1991;37:340-3.
15. Mellemgaard A, Enghoim G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark. I. Role of socioeconomic status, tobacco use, beverages, and family history. Cancer Causes Control 1994;5:105-13.
16. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989;68:1-29.
17. Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592-5.
18. Pathak S, Strong LC, Ferrell RE, Trindade A. Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science 1982;217:939-41.
19. Kovacs G, Brusa P, De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989;43:422-7
20. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol 1994;151:561-6.
21. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986;181:125-43.
22. van den Berg E, van der Hout AH, Oosterhuis JW, et al. Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classification. Int J Cancer 1993;55:223-7.
23. Weiss LM, Gelb AB, Medeiros LI. Adult renal epithelial neoplasms. Am J Clin Pathol 1995;103:624-35.
24. Storkel S, Steart PV, Drenckhaln D, Thoenes W. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 56:237-45.
25. Akhtar M, Kardar H, Linjawi T, McClintock J, Ali MA. Chromophobe cell carcinoma of the kidney: a clinicopathologic study of 21 cases. Am J Surg Pathol 1995;19:1245-56.
26. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994;145: 356-64.
27. Storkel S, van den Berg E. Morphological classification of renal cancer. World J Urol 1995;13:153-8.
28. Presti JC Jr, Rao PH, Chen Q, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 1991; 51:1544-52.
29. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
30. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic: a study of 42 cases. Cancer 1987;59: 516-26.
31. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 1976; 38:2469-80
32. Kovacs G, Wilkens L, Papp T, de Riese W. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst 1989;81:527-30.
33. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosom Cancer 1991;3:249-55.
34. Sene AP, Hunt L, McMahon RF, Carroll RN. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol 1992;70:125-34.
35. Bander NH, Finstad CL, Cordon-Cardo C, et al. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. Cancer Res 1989;49: 6774-80.
36. Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosom Cancer 1992;4:267-8.
37. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 1995;154:964-7.
38. Morra MN, Das S. Renal oncocytoma: a review of histogenesis, histopathology, diagnosis and treatment. J Urol 1993;150:295-302.
39. Kennedy SM, Merino MJ, Linehan WM, Roberts JR, Robertson CN, Neumann RD. Collecting duct carcinoma of the kidney. Hum Pathol 1990;21:449-56.
40. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987;327: 721-4.
41. Maher ER, Yates JRW. Familial renal cell carcinoma: clinical and molecular genetic aspects. Br J Cancer 1991;63:176-9.
42. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-9.
43. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
44. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
45. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
46. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
47. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
48. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269:1444-6.
49. Chen F, Kishida T, Duh FM, et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995;55:4804-7.
50. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
51. Thrash-Bingham CA, Salazar H, Freed JJ, Greenberg RE, Tartof KD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 1995;55:6189-95.
52. Moch H, Presti JC Jr, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996;56:27-30.
53. Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J Urol 1994;12:162-8.
54. van den Berg A, Hulsbeek MMF, de Jong D, et al. Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Genes Chromosom Cancer 1996;15:64-72.
55. Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K. Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol 1993;150:1298-301.
56. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 Mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994;7:766-70.
57. Kikuchi Y, Kishi T, Suzuki M, Furusato M, Aizawa S. Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas. Virchows Arch A Pathol Anat Histopathol 1994;424:229-33.
58. Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994;57:634-7.
59. Uhlman DL, Nguyen PL, Manivel JC, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994;86: 1470-5.
60. Lipponen P, Eskelinen M, Syrjanen K. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995;71: 863-7.
61. Walther MM, Gnarra JR, Elwood L, et al. Loss of heterozygosity occurs centromeric to RB without associated abnormalities in the retinoblastoma gene in tumors from patients with metastatic renal cell carcinoma. J Urol 1995;153:2050-4.
62. Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-4.
63. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995;55:224-7.
64. Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP. Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 1990; 143:175-8.
65. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activatcd protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
66. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD, Fair WR. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989;49:3407-11.
67. Uhlman DL, Nguyen P, Manivel JC, et al. Epidermal growth foctor receptor and transforming growth factor α expression in papillary and non-papillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1995;1:913-20.
68. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 1992;52:3335-9.
69. Kellerer M, von Eye Corleta H, Muhlhofer A, et al. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer 1995;62:501-7.
70. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993;85:1597-9.
71. Berger DP, Herbstritt L, Dengler WA, Marme D, Mertelsmann R, Fiebig HH. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 1995;6:817-25.
72. Fidler IJ. The biology of renal cancer metastasis. Semin Urol 1992;10: 3-11.
73. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988;48:6753-7.
74. Anglard P, Tory K, Brauch H, et al. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 1991;51:1071-7.
75. Brooks JD, Bova GS, Marshall FF, Isaacs WB. Tumor suppressor gene allelic loss in human renal cancers. J Urol 1993;150:1278-83.
76. Kanayama H, Takigawa H, Kagawa S. Analysis of nm23 gene expressions in human bladder and renal cancers. Int J Urol 1994;1:324-31.
77. Walther MM, Anglard P, Gnarra J, et al. Expression of nm23 in cell lines derived from patients with metastatic renal cell carcinoma. J Urol 1995;154:278-82.
78. Suzuki Y, Tamura G, Maesawa C, Fujioka T, Kubo T, Satodate R, Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction. Virchows Arch A Pathol Anat Histopathol 1994;424:453-7. [Erratum, Virchows Arch A Pathol Anat Histopathol 1994;425:335.]
79. Ritchie AWS, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390-400.
80. Porena M, Vespasiani G, Rosi P, et al. Incidentally detected renal cell carcinoma: role of ultrasonography. J Clin Ultrasound 1992;20:395-400.
81. Hellsten S, Berge T, Whelin L. Unrecognized renal cell carcinoma: clinical and diagnostic aspects. Scand J Urol Nephrol 1981;15:269-72.
82. Konnack JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol 1985;134:1094-6.
83. Thompson IM, Peek M. Improvement in survival of patients with renal cell carcinoma - the role of the serendipitously detected tumor. J Urol 1988;140:487-90.
84. Smith SJ, Bosniak MA, Megibow AJ, Hulnick DH, Horii SC, Raghavendra BN. Renal cell carcinoma: earlier discovery and increased detection. Radiology 1989;170:699-703.
85. Nseyo UO, Williams PD, Murphy GP. Clinical significance of erythropoietin levels in renal carcinoma. Urology 1986;28:301-6.
86. Gotoh A, Kitazawa S, Mizuno Y, et al. Common expression of parathyroid hormone-related protein and no correlation of calcium level in renal cell carcinomas. Cancer 1993;71:2803-6.
87. Cronin RE, Kaehny WD, Miller PD, et al. Renal cell carcinoma: unusual systemic manifestations. Medicine (Baltimore) 1976;55:291-311.
88. Warshauer DM, McCarthy SM, Street L, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology 1988;169:363-5.
89. Amendola MA, Bree RL, Pollack HM, et al. Small renal cell carcinomas: resolving a diagnostic dilemma. Radiology 1988;166:637-41.
90. Johnson CD, Dunnick NR, Cohan RH, Illescas FE Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 1987;148:59-63.
91. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990;144:243-5.
92. Semelka RC, Shoenut IP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhancing fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993;3:597-602.
93. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991;180: 85-9.
94. Bosniak MA. The small (≤3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology 1991;179:307-17. [Erratum, Radiology 1991;181:289.]
95. Idem. The current radiological approach to renal cysts. Radiology 1986;158:1-10.
96. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
97. Sagalowsky AI, Kadesky KT, Ewait DM, Kennedy TJ. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 1994;151:1181-4.
98. Shalev M, Cipolla B, Guille F, Staerman F, Lobel B. Is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol 1995; 153:1415-7.
99. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol 1994;152:1082-5.
100. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990;143:468-74.
101. Phillips PE, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 1993;41:9-15.
102. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991;146:1224-7.
103. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990;144:852-8.
104. Moll V, Becht E, Ziegler M. Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients. J Urol 1993; 150:319-23.
105. Steinbach F, Stockle M, Muller SC, et al. Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 1992;148: 24-9.
106. Licht MR, Novick AC, Goormastic M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 1994;152:39-42.
107. Thrasher JB, Robertson JE, Paulson DF. Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 1994;43: 160-8.
108. Novick AC, Streem SB, Montie JE, et al. Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 1989;141:835-9.
109. Marberger M, Pugh RO, Auvert J, et al. Conservation surgery of renal carcinoma: the EIRSS experience. Br J Urol 1981;53:528-32.
110. Steinbach F, Stockle M, Hohenfellner R. Current controversies in nephron-sparing surgery for renal-cell carcinoma. World J Urol 1995;13: 163-5.
111. Provet J, Tessler A, Brown J, Golimbu M, Bosniak M, Morales E Partial nephrectomy for renal cell carcinoma: indications, results and implications. J Urol 1991;145:472-6.
112. Whang M, O'Toole K, Bixon R, et al. The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol 1995;154:968-71.
113. Herr HW. Partial nephrectomy for renal cell carcinoma with a normal opposite kidney. Cancer 1994;73:160-2.
114. Saitoh H, Nakayama M, Nakamura K, Satoh T. Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 1982;127: 1092-5
115. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
116. Cherrie RJ, Goldman DG, Lindner A, deKernion JB. Prognostic implications of vena caval extension or renal cell carcinoma. J Urol 1982;128: 910-2.
117. Marshall FF, Dietrick DD, Baumgartner WA, Reitz BA. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol 1988;139:1166-72.
118. Novick AC. Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renalcell carcinoma. Semin Oncol 1995;22:29-33.
119. Couillard DR, deVere White RW. Surgery of renal cell carcinoma. Urol Clin North Am 1993;20:263-75.
120. McCaffrey JA, Motzer RJ. What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996;23:xix-xx.
121. Robertson CN, Linehan WM, Pass HI, et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990;144:614-8.
122. Rackley RR, Klein EA, Novick AD. Morbidity and mortality of primary adjuvant nephrectomy in immunotherapy for renal cell carcinoma. J Urol 1991;145:Suppl:422A. abstract.
123. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993;20:247-62.
124. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Handbook for staging of cancer: from the manual for staging of cancer. 4th ed. Philadelphia: J.B. Lippincott, 1993.
125. Kidney cancer: a report by 97 Illinois hospitals on cases diagnosed in 1975-85. Report no. 12 of Results in treating cancer. Chicago: American Cancer Society, 1989.
126. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995;154:28-31.
127. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206-12.
128. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma: a randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987;13: 665-72.
129. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
130. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-65.
131. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128-31.
132. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
133. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283-95.
134. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
135. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76: 824-32.
136. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
137. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 1990;50:4190-4.
138. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368-75.
139. Fossa SD, Martinelli G, Otto U, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992;3:301-5.
140. Neidhart JA, Anderson SA, Harris JE, et al. Vinblastine fails to improve response of renal cancer to Interferon alfa-nl: high response rate in patients with pulmonary metastases. J Clin Oncol 1991;9:832-6.
141. Krown SE. Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 1987;59:647-51.
142. Fossa SD, Raabe N, Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma: results of a randomised phase II study. Br J Urol 1989;64:468-71.
143. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie A. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
144. Hänninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
145. Motzer RJ, Schwartz L, Law TM, et al. Interferon alfa-2a and 13-cisretinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-7.
146. Pierce WC, Belldegrun A, Figlin RA. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995;22:74-80.
147. Gastl G, Finstad CL, Guarini A, et al. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992; 52:6229-36.
148. Belldegrun A, Tso CL, Sakata T, et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 1993;85:207-16.
149. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996;88:38-43.
150. Hoffman AD, Engelstein D, Bogenricder T, et al. Expression of retinoic acid receptor β in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996;2:1077-82.